Christian Diercks

Our new company, K2 Therapeutics, is off to the races to develop antibody drugs that target multipass membrane proteins. We are hiring so check us out! #careers" target="_blank" rel="nofollow noopener">k2-tx.com/home#careers

T7-ORACLE Foretells Functional Proteins by Accelerating Evolution The #syntheticbiology platform accelerates protein evolution thousands of times faster than nature for broad therapy applications @scrippsresearch #proteins #antibodies #enzymes hubs.li/Q03C7zjy0

Scientists in the lab of Peter Schultz, the President and CEO of Scripps Research, and assistant professor Christian Diercks (@DiercksLab) have developed a synthetic biology platform that accelerates evolution itself—enabling researchers to evolve proteins with useful, new properties thousands of times faster than nature, and bypassing the slow, laborious methods currently used in medicine and biotechnology. The T7-ORACLE orthogonal system targets only plasmid DNA (small, circular pieces of genetic material), leaving the cell’s host genome untouched. It has the potential to help scientists more rapidly evolve antibodies to target specific cancers, evolve more effective therapeutic enzymes, and design proteases that target proteins involved in cancer and neurodegenerative disease. More at: ow.ly/C8AJ50WEKgm

Happy to see this new T7 replicon based orthogonal replication system in E. coli. Congrats to the Diercks and Schultz lab teams at Scripps Research! science.org/doi/10.1126/sc…

An Orthogonal T7 Replisome for Continuous Hypermutation and Accelerated Evolution in E. coli biorxiv.org/cgi/content/sh… #biorxiv_synbio

Happy to share the publication of our latest manuscript in Science! With Peter Schultz's lab and my team at Scripps Research we developed T7-ORACLE – an orthogonal replication system for continuous hypermutation and accelerated evolution in E. coli. science.org/doi/10.1126/sc…

Super honored and thrilled to receive the Michelson Prize: Next Generation Grant! Thank you #MichelsonPrizes for the support as we work hard toward developing better and safer vaccine adjuvants. I'm grateful for this opportunity, and very excited for the journey ahead!

Thrilled to share our work using microbial cell factory to investigate strigoractone biosynthesis and evolution. So fortunate to work with such an amazing team of scientists. @nelson_lab @ShabekLab science.org/doi/10.1126/sc…

Interested in continuous evolution of biomacromolecules or in the development of Darwinian nanoparticles for gene delivery! Then apply to be a postdoctoral researcher in the Diercks Lab at Scripps. More information at dierckslab.com or at recruiting2.ultipro.com/SCR1003TSRI/Jo…

I am excited to share two preprints from out lab showing the ability of organophotocatalysts for mild partial reductions of benzenes and alkynes. Great work by Kirti, Asad, Benni, Dang, and Henric! chemrxiv.org/engage/chemrxi… chemrxiv.org/engage/chemrxi…

In this account, Peter Schultz describes some major themes and projects from his group and career at the interface of chemistry and biology. What legendary science and scientists with much more ahead! I'm grateful to have been among his PhD students. pubs.acs.org/doi/10.1021/ac…

Prof. Yuzhong Liu is pioneering a sustainable method to produce QS-21, a highly sought-after molecule that improves vaccine effectiveness in yeast. This innovative approach reduces environmental impact and makes vaccines more accessible. Read the full Q+A: ow.ly/Blw150Snzc3